Heartpoint’s IntelliStent system is designed to use minimally invasive catheter delivery to place adjustable stents that adjust blood flow in the pulmonary arteries. [Illustration courtesy of Heartpoint]
By Seth Bogner, HeartPoint GlobalIn pediatric cardiology, a persistent challenge revolves around ensuring accessible and effective care for children grappling with congenital heart disease (CHD). CHD affects approximately 1.7% of newborns globally, or 2.4 million, of which 90% have the urgent need for affordable and specialized treatments that call for innovative solutions.
According to a recent article in The Journal of the American College of Cardiology (JACC), economic constraints in many developing nations contribute to delayed diagnosis and treatment for up to 90% of children with CHD, leading to severe consequences such as organ dysfunction and complications like profound cyanosis and polycy…